Zentalis Pharmaceuticals Llc Stock Analysis

ZNTL Stock  USD 4.01  0.31  8.38%   
Zentalis Pharmaceuticals Llc is undervalued with Real Value of 15.14 and Target Price of 49.6. The main objective of Zentalis Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Zentalis Pharmaceuticals Llc is worth, separate from its market price. There are two main types of Zentalis Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Zentalis Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Zentalis Stock Analysis Notes

About 96.0% of the company outstanding shares are owned by institutional investors. The book value of Zentalis Pharmaceuticals was at this time reported as 6.46. The company recorded a loss per share of 3.26. Zentalis Pharmaceuticals had not issued any dividends in recent years. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. For more information please call Kimberly MD at 212 433 3791 or visit https://zentalis.com.

Zentalis Pharmaceuticals Investment Alerts

Zentalis Pharmaceuticals generated a negative expected return over the last 90 days
Zentalis Pharmaceuticals has high historical volatility and very poor performance
Zentalis Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0.
Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 96.0% of the company outstanding shares are owned by institutional investors
Latest headline from benzinga.com: SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Zentalis Pharmaceuticals Upcoming and Recent Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Zentalis Largest EPS Surprises

Earnings surprises can significantly impact Zentalis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-09
2020-09-30-0.81-0.91-0.112 
2023-11-06
2023-09-30-0.91-0.790.1213 
2023-03-01
2022-12-31-1.06-0.920.1413 
View All Earnings Estimates

Zentalis Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Zentalis Pharmaceuticals' ESG score is a quantitative measure that evaluates Zentalis Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Zentalis Pharmaceuticals' operations that may have significant financial implications and affect Zentalis Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Zentalis Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Mpm Oncology Impact Management Lp2024-03-31
1.5 M
Woodline Partners Lp2024-03-31
1.4 M
Geode Capital Management, Llc2024-03-31
1.3 M
Primecap Management Company2024-03-31
1.2 M
Verition Fund Managegment, Llc2024-03-31
1.2 M
Morgan Stanley - Brokerage Accounts2024-03-31
M
Tybourne Capital Management (hk) Ltd2024-03-31
961.5 K
Paradigm Biocapital Advisors Lp2024-03-31
944.9 K
Dimensional Fund Advisors, Inc.2024-03-31
723.7 K
Matrix Capital Management Company, Llc2024-03-31
14 M
Eventide Asset Management, Llc2024-03-31
11.6 M
Note, although Zentalis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Zentalis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 262.75 M.

Zentalis Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.52)(0.55)
Return On Capital Employed(0.52)(0.54)
Return On Assets(0.52)(0.55)
Return On Equity(0.67)(0.70)

Management Efficiency

Zentalis Pharmaceuticals has return on total asset (ROA) of (0.2493) % which means that it has lost $0.2493 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5187) %, meaning that it created substantial loss on money invested by shareholders. Zentalis Pharmaceuticals' management efficiency ratios could be used to measure how well Zentalis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.55. The value of Return On Capital Employed is expected to slide to -0.54. At this time, Zentalis Pharmaceuticals' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 7.2 M this year, although the value of Non Current Assets Total will most likely fall to about 56.8 M.
Last ReportedProjected for Next Year
Book Value Per Share 6.69  4.67 
Tangible Book Value Per Share 6.63  4.55 
Enterprise Value Over EBITDA(3.99)(4.19)
Price Book Value Ratio 2.27  2.15 
Enterprise Value Multiple(3.99)(4.19)
Price Fair Value 2.27  2.15 
Enterprise Value1.9 B1.1 B
The analysis of Zentalis Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Zentalis Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Zentalis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
(0.61)
Beta
1.705
Return On Assets
(0.25)
Return On Equity
(0.52)

Technical Drivers

As of the 22nd of July, Zentalis Pharmaceuticals maintains the Mean Deviation of 4.61, standard deviation of 8.54, and Market Risk Adjusted Performance of (0.45). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zentalis Pharmaceuticals Llc, as well as the relationship between them. Please check out Zentalis Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Zentalis Pharmaceuticals is priced fairly, providing market reflects its latest price of 4.01 per share. Given that Zentalis Pharmaceuticals Llc has information ratio of (0.18), we strongly advise you to confirm Zentalis Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.

Zentalis Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Zentalis Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Zentalis Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Zentalis Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zentalis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zentalis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zentalis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Zentalis Pharmaceuticals Outstanding Bonds

Zentalis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zentalis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zentalis bonds can be classified according to their maturity, which is the date when Zentalis Pharmaceuticals Llc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Zentalis Pharmaceuticals Predictive Daily Indicators

Zentalis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zentalis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Zentalis Pharmaceuticals Corporate Filings

8K
21st of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
31st of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
29th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
9th of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
7th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
29th of April 2024
Other Reports
ViewVerify
8K
11th of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Zentalis Pharmaceuticals Forecast Models

Zentalis Pharmaceuticals' time-series forecasting models are one of many Zentalis Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zentalis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Zentalis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Zentalis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Zentalis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Zentalis Pharmaceuticals. By using and applying Zentalis Stock analysis, traders can create a robust methodology for identifying Zentalis entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin-1.5 K-1.6 K
Operating Profit Margin-1.5 K-1.6 K
Net Loss-1.4 K-1.4 K

Current Zentalis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Zentalis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Zentalis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
49.6Buy11Odds
Zentalis Pharmaceuticals Llc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Zentalis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Zentalis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Zentalis Pharmaceuticals, talking to its executives and customers, or listening to Zentalis conference calls.
Zentalis Analyst Advice Details

Zentalis Stock Analysis Indicators

Zentalis Pharmaceuticals Llc stock analysis indicators help investors evaluate how Zentalis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Zentalis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Zentalis Pharmaceuticals stock analysis, traders can identify Zentalis Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow43.1 M
Common Stock Shares Outstanding65.4 M
Total Stockholder Equity437.3 M
Tax Provision-826 K
Property Plant And Equipment Net41.7 M
Cash And Short Term Investments482.9 M
Cash28 M
Accounts Payable14.9 M
Net Debt17.7 M
50 Day M A8.1271
Total Current Liabilities69.4 M
Other Operating Expenses253.9 M
Non Current Assets Total65.3 M
Non Currrent Assets Other6.8 M
Stock Based Compensation54.8 M

Additional Information and Resources on Investing in Zentalis Stock

When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.26)
Revenue Per Share
0.594
Return On Assets
(0.25)
Return On Equity
(0.52)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.